May 15th 2024
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
James Allison Receives Distinguished Scientist Award From Association of American Cancer Institutes
October 27th 2016James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer research.
Read More
High Response Rates Observed with Ipilimumab Plus Nivolumab in Advanced Melanoma
October 11th 2016Combined ipilimumab and nivolumab administered pre- and post-surgery reduced the tumor burden in patients with Stage III B/C melanoma, according to first results from the OpACIN trial reported at the ESMO 2016 Annual Congress.
Read More
Significant Disparities in Access to Novel Agents For Patients With Melanoma
October 9th 2016Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Watch
Thousands of Metastatic Melanoma Patients in Europe Without Access to Novel Agents
October 8th 2016Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives, according to a survey presented at the 2016 ESMO Congress.
Read More
Combination of Encorafenib and Binimetinib Improves PFS in Melanoma
September 26th 2016Part 1 of the phase III COLUMBUS trial has shown positive results for the combination of the BRAF inhibitor encorafenib (LGX818) and the MEK inhibitor binimetinib (MEK162) for patients with <em>BRAF</em>-mutant melanoma.
Read More
Advances in Image-Guided Oncologic Treatment
September 21st 2016Advances in the computerization of the imaging, blood flow, and tumor measures of exact volume and vessel density are now less operator dependent. That provides for an accurate and repeatable diagnosis, and a means to follow the individual patient’s unique pattern of cancer development, progress, and response to treatment.
Read More
Weber Speaks on Findings of Immunotherapy Study in Melanoma
September 2nd 2016<div>Though Nivolumab (Opdivo) and ipilimumab (Yervoy) have demonstrated considerable success in the field of metastatic melanoma as both single agents and in combination, questions remain regarding sequencing the agents and the high toxicities that often occur when the 2 immunotherapies are used together.<br /> </div>
Read More